|
Jan 10
|
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?
|
|
Dec 7
|
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
|
|
Dec 6
|
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
|
|
Dec 4
|
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
|
|
Nov 27
|
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
|
|
Sep 21
|
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
|
|
Sep 20
|
89bio to Participate in the 2023 Cantor Global Healthcare Conference
|
|
Sep 9
|
89bio Insider Ups Holding By 41% During Year
|
|
Sep 5
|
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Jun 24
|
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
|
|
Jun 24
|
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
|
|
May 2
|
89bio to Participate in Upcoming Investor Conferences
|
|
Apr 29
|
3 Biotech Buyout Targets to Watch
|